inclusion criteria: * has documentation of polymerase chain reaction (pcr)-confirmed severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection with sample collection ≤ 10 days prior to the day of randomization. pcr is the preferred method; however other diagnostic methods are allowed if authorized by use in the country * had initial onset of signs/symptoms attributable to covid-19 for ≤10 days prior to the day of randomization and ≥1 sign/symptom attributable to covid-19 present at randomization * requires medical care in the hospital for ongoing clinical manifestations of covid-19 (not just for public health or quarantine purposes) * has mild, moderate, or severe covid-19 * is willing and able to take oral medication * males agree to the following during the intervention period and for at least 90 days after the last dose of study intervention: refrain from donating sperm; and either abstain from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; or must agree to use contraception * females are not pregnant or breastfeeding, and at least one of the following conditions applies: is not a woman of child bearing potential (wocbp); or is a wocbp and using a contraceptive method that is highly effective (a low user dependency method or a user dependent method in combination with barrier method), or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) for 28 days from the start of study intervention; a wocbp must have a negative highly sensitive pregnancy test (serum test is required) within 24 hours before the first dose of study intervention

inclusion criteria: * has documentation of polymerase chain reaction (pcr)-confirmed severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection with sample collection ≤ 10 days prior to the day of randomization. pcr is the preferred method; however other diagnostic methods are allowed if authorized by use in the country * had initial onset of signs/symptoms attributable to covid-19 for ≤10 days prior to the day of randomization and ≥1 sign/symptom attributable to covid-19 present at randomization * requires medical care in the hospital for ongoing clinical manifestations of covid-19 (not just for public health or quarantine purposes) * has mild, moderate, or severe covid-19 * is willing and able to take oral medication * males agree to the following during the intervention period and for at least 90 days after the last dose of study intervention: refrain from donating sperm; and either abstain from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; or must agree to use contraception * females are not pregnant or breastfeeding, and at least one of the following conditions applies: is not a woman of child bearing potential (wocbp); or is a wocbp and using a contraceptive method that is highly effective (a low user dependency method or a user dependent method in combination with barrier method), or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) for 28 days from the start of study intervention; a wocbp must have a negative highly sensitive pregnancy test (serum test is required) within 24 hours before the first dose of study intervention

inclusion criteria: - has documentation of polymerase chain reaction (pcr)-confirmed severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection with sample collection ≤ 10 days prior to the day of randomization. pcr is the preferred method; however other diagnostic methods are allowed if authorized by use in the country - had initial onset of signs/symptoms attributable to covid-19 for ≤10 days prior to the day of randomization and ≥1 sign/symptom attributable to covid-19 present at randomization - requires medical care in the hospital for ongoing clinical manifestations of covid-19 (not just for public health or quarantine purposes) - has mild, moderate, or severe covid-19 - is willing and able to take oral medication - males agree to the following during the intervention period and for at least 90 days after the last dose of study intervention: refrain from donating sperm; and either abstain from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; or must agree to use contraception - females are not pregnant or breastfeeding, and at least one of the following conditions applies: is not a woman of child bearing potential (wocbp); or is a wocbp and using a contraceptive method that is highly effective (a low user dependency method or a user dependent method in combination with barrier method), or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) for 28 days from the start of study intervention; a wocbp must have a negative highly sensitive pregnancy test (serum test is required) within 24 hours before the first dose of study intervention

inclusion criteria: - has documentation of polymerase chain reaction (pcr)-confirmed severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection with sample collection ≤ 10 days prior to the day of randomization. pcr is the preferred method; however other diagnostic methods are allowed if authorized by use in the country - had initial onset of signs/symptoms attributable to covid-19 for ≤10 days prior to the day of randomization and ≥1 sign/symptom attributable to covid-19 present at randomization - requires medical care in the hospital for ongoing clinical manifestations of covid-19 (not just for public health or quarantine purposes) - has mild, moderate, or severe covid-19 - is willing and able to take oral medication - males agree to the following during the intervention period and for at least 90 days after the last dose of study intervention: refrain from donating sperm; and either abstain from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; or must agree to use contraception - females are not pregnant or breastfeeding, and at least one of the following conditions applies: is not a woman of child bearing potential (wocbp); or is a wocbp and using a contraceptive method that is highly effective (a low user dependency method or a user dependent method in combination with barrier method), or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) for 28 days from the start of study intervention; a wocbp must have a negative highly sensitive pregnancy test (serum test is required) within 24 hours before the first dose of study intervention

inclusion criteria: - has documentation of polymerase chain reaction (pcr)-confirmed severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection with sample collection ≤ 10 days prior to randomization. pcr is the preferred method; however other diagnostic methods are allowed if authorized by use in the country. - had initial onset of signs/symptoms attributable to covid-19 for ≤10 days prior to randomization and ≥1 sign/symptom attributable to covid-19 present at randomization. - requires medical care in the hospital for ongoing clinical manifestations of covid-19 (not just for public health or quarantine purposes). - is willing and able to take oral medication. - males agree to the following during the intervention period and for at least 90 days after the last dose of study intervention: refrain from donating sperm; and either abstain from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; or must agree to use contraception. - females are not pregnant or breastfeeding, and at least one of the following conditions applies: is not a woman of child bearing potential (wocbp); or is a wocbp and using a contraceptive method that is highly effective (a low user dependency method or a user dependent method in combination with barrier method), or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) during the intervention period and for at least 7 months after the last dose of study intervention; a wocbp must have a negative highly sensitive pregnancy test (serum test is required) within 24 hours before the first dose of study intervention.

inclusion criteria: - has documentation of polymerase chain reaction (pcr)-confirmed severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection with sample collection ≤ 10 days prior to randomization. pcr is the preferred method; however other diagnostic methods are allowed if authorized by use in the country. - had initial onset of signs/symptoms attributable to covid-19 for ≤10 days prior to randomization and ≥1 sign/symptom attributable to covid-19 present at randomization. - requires medical care in the hospital for ongoing clinical manifestations of covid-19 (not just for public health or quarantine purposes). - is willing and able to take oral medication. - males agree to the following during the intervention period and for at least 90 days after the last dose of study intervention: refrain from donating sperm; and either abstain from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; or must agree to use contraception. - females are not pregnant or breastfeeding, and at least one of the following conditions applies: is not a woman of child bearing potential (wocbp); or is a wocbp and using a contraceptive method that is highly effective (a low user dependency method or a user dependent method in combination with barrier method), or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) during the intervention period and for at least 7 months after the last dose of study intervention; a wocbp must have a negative highly sensitive pregnancy test (serum test is required) within 24 hours before the first dose of study intervention.